neoLaser Laser Surgery Fibers

K250113 · G.N.S Neolaser , Ltd. · GEX · Mar 13, 2025 · General, Plastic Surgery

Device Facts

• Record ID: K250113
• Device Name: neoLaser Laser Surgery Fibers
• Applicant: G.N.S Neolaser , Ltd.
• Product Code: GEX · General, Plastic Surgery
• Decision Date: Mar 13, 2025
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 878.4810
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The Fibers are indicated for use in general surgical applications for incision, vaporization, ablation, hemostasis or coagulation of soft tissue. It is also indicated for use in open or closed endoscopic applications where incision, excision, tissue dissection, excision of external tumors and lesions, complete or partial resection of internal organs, tumors or lesions, tissue vaporization, hemostasis and or coagulation may be indicated. The neoLaser Laser Surgery Fibers have a wavelength range of 450 nm to 2100 nm, can be used in contact mode and are indicated for use in general surgery, urology, gastroenterology, dermatology, vascular surgery, neurosurgery, plastic surgery, ENT and endovenous occlusion of the greater saphenous vein in the patient with superficial vein reflux and laser assisted lipolysis with a cleared compatible laser marketed for the mentioned intended uses and using an SMA 905 connector.

Device Story

Sterile, single-use fiber optic delivery system; transmits laser energy from external laser source to soft tissue; operates in contact or non-contact modes; includes aiming beam for target visualization; connects via SMA 905 connector; used by physicians in surgical settings; enables precise tissue interaction (incision, ablation, coagulation); benefits include minimally invasive surgical access and controlled tissue destruction/hemostasis.

Clinical Evidence

Bench testing only. Includes packaging seal strength, dye penetration, microbial barrier, shelf-life, sterilization validation (EO), SAL, ECH residuals, LAL endotoxin, bioburden, biocompatibility, and thermal safety validation. No clinical or animal studies performed.

Technological Characteristics

Silica quartz glass core; silica/Hardclad cladding; silicone buffer; various jacket materials (ETFE, nylon, etc.); SMA 905 connector; 450-2100 nm wavelength range; up to 100W power; sterile by EO; single-use.

Indications for Use

Indicated for patients requiring soft tissue incision, excision, vaporization, ablation, hemostasis, or coagulation in general, endoscopic, urological, gastroenterological, gynecological, dermatological, vascular, neurosurgical, plastic, and ENT surgeries; includes endovenous occlusion for superficial vein reflux and laser-assisted lipolysis.

Regulatory Classification

Identification

(1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.

Predicate Devices

• BeaMed Laser Surgery Fibers (K232769)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

March 13, 2025

G.N.S neoLaser Ltd. Gil Shapira CEO Ha'Eshel St. 7 Caesarea, 3088900 Israel

Re: K250113

Trade/Device Name: neoLaser Laser Surgery Fibers Regulation Number: 21 CFR 878.4810 Regulation Name: Laser surgical instrument for use in general and plastic surgery and in dermatology Regulatory Class: Class II Product Code: GEX Dated: January 8, 2025 Received: January 16, 2025

Dear Gil Shapira:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"

{1}------------------------------------------------

(https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review. the OS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rue"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advicecomprehensive-regulatory-assistance/unique-device-identification-system-udi-system.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

{2}------------------------------------------------

Sincerely,

Image /page/2/Picture/3 description: The image shows a digital signature. The name "YAN FU" is prominently displayed on the left side of the image. To the right of the name, the text "Digitally signed by YAN FU" is present, along with the date and time "2025.03.13 17:18:32 -04'00'." The signature indicates that the document has been digitally signed by YAN FU on March 13, 2025, at 5:18:32 PM with a time zone offset of -04'00'.

for Tanisha Hithe Assistant Director DHT4A: Division of General Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{3}------------------------------------------------

# Indications for Use

510(k) Number (if known) K250113

Device Name neoLaser Laser Surgery Fibers

#### Indications for Use (Describe)

The Fibers are indicated for use in general surgical applications for incision, vaporization, ablation, hemostasis or coagulation of soft tissue. It is also indicated for use in open or closed endoscopic applications where incision, excision, tissue dissection, excision of external tumors and lesions, complete or partial resection of internal organs, tumors or lesions, tissue vaporization, hemostasis and or coagulation may be indicated. The neoLaser Laser Surgery Fibers have a wavelength range of 450 nm to 2100 nm, can be used in contact mode and are indicated for use in general surgery, urology, gastroenterology, dermatology, vascular surgery, neurosurgery, plastic surgery, ENT and endovenous occlusion of the greater saphenous vein in the patient with superficial vein reflux and laser assisted lipolysis with a cleared compatible laser marketed for the mentioned intended uses and using an SMA 905 connector.

| Type of Use (Select one or both, as applicable) | |
|-------------------------------------------------|--|
|-------------------------------------------------|--|

X Prescription Use (Part 21 CFR 801 Subpart D)

| Over-The-Counter Use (21 CFR 801 Subpart C)

### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{4}------------------------------------------------

Image /page/4/Picture/0 description: The image is a square with a black background. In the lower left corner, the word "neolaser" is written in white font. There is a green line that runs underneath the word "neolaser".

7 HaEshel St., Caesarea 3088900, ISRAEL | Tel: [phone] | Fax: [phone] [e-mail] | www.neo-laser.com

## K250113 - neoLaser Laser Surgery Fibers - Traditional Submission - 510(k) Summary

### Submitter: G.N.S neoLaser Ltd. (neoLaser) 7 HaEshel St. Caesarea 3088900 Israel Contact person: Gil Shapira, CEO [phone] Phone: Fax : + 972 4 8591505 [e-mail] e-Mail: Type of 510(k) Traditional Date January 8, 2025 Prepared: Device Trade Name: neoLaser Laser Surgery Fibers Common Name: Fiber optic laser delivery system Classification Name: General and Plastic Surgery Device product code: GEX Device Classification: 21 CFR 878.4810 Predicate: BeaMed Laser Surgery Fibers (K232769)

# Device Description:

The neoLaser Laser Surgery Fibers are sterile, single use, laser delivery devices intended for medical applications in various fields of laser surgery. They are intended to deliver energy to soft tissue in contact and non-contact mode during various surgical applications, including via endoscopes and cytoscopes. The fibers are designed to transmit energy from the laser system to the treatment site, as well as to transmit a low power laser aiming beam to assist in the visibilty of the target tissue.

{5}------------------------------------------------

Image /page/5/Picture/0 description: The image is a square logo with rounded corners. The background is black, and the words "neo laser" are written in a sans-serif font. The word "neo" is in a lime green color, and the word "laser" is in white. There is a thin lime green line separating the two words.

7 HaEshel St., Caesarea 3088900, ISRAEL | Tel: [phone] | Fax: [phone] [e-mail] | www.neo-laser.com

# Indications for Use:

The Fibers are indicated for use in general surgical applications for incision, excision. vaporization, ablation, hemostasis or coagulation of soft tissue. It is also indicated for use in open or closed endoscopic applications where incision, tissue dissection, excision of external tumors and lesions, complete or partial resection of internal organs, tumors or lesions, tissue vaporization, hemostasis and or coagulation may be indicated.

The neoLaser Laser Surgery Fibers have a wavelength range of 450 nm to 2100 nm, can be used in contact and non-contact mode and are indicated for use in general surgery, urology, gastroenterology, gynecology, dermatology, vascular surgery, neurosurgery, plastic surgery, ENT and endovenous occlusion of the greater saphenous vein in the patient with superficial vein reflux and laser assisted lipolysis with a cleared compatible laser marketed for the mentioned intended uses and using an SMA 905 connector.

| Specification | Subject Device<br>neoLaser Laser Surgery Fibers | Predicate Device<br>BeaMed Laser Surgery Fibers |
|-----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 510(k) | Pending | K232769 |
| Indications for<br>Use | The Fibers are indicated for use in<br>general surgical applications for<br>incision, excision, vaporization,<br>ablation, hemostasis or coagulation<br>of soft tissue. It is also indicated for<br>use in open or closed endoscopic<br>applications where incision,<br>excision,tissue dissection, excision of<br>external tumors and lesions, complete<br>or partial resection of internal organs,<br>tumors or lesions, tissue<br>vaporization, hemostasis and or<br>coagulation may be indicated.<br><br>The neoLaser Laser Surgery Fibers<br>have a wavelength range of 450 nm<br>to 2100 nm, can be used in contact<br>and non-contact mode and are<br>indicated for use in general surgery,<br>urology, gastroenterology,<br>gynecology, dermatology, vascular<br>surgery, neurosurgery, plastic<br>surgery, ENT and endovenous<br>occlusion of the greater saphenous | The Fibers are indicated for use<br>in general surgical applications<br>for incision, excision,<br>vaporization, ablation,<br>hemostasis or coagulation of soft<br>tissue. It is also indicated for use<br>in open or closed endoscopic<br>applications where incision,<br>excision,tissue dissection,<br>excision of external tumors and<br>lesions, complete or partial<br>resection of internal organs,<br>tumors or lesions, tissue<br>vaporization, hemostasis and or<br>coagulation may be indicated.<br><br>The BeaMed Laser Surgery<br>Fibers have a wavelength range<br>of 450 nm to 2100 nm, can be<br>used in contact and non-contact<br>mode and are indicated for use in<br>general surgery, urology,<br>gastroenterology, gynecology, |
| | vein in the patient with superficial<br>vein reflux and laser assisted<br>lipolysis with a cleared<br>compatible laser marketed for the<br>mentioned intended uses and using<br>an SMA 905 connector. | dermatology, vascular surgery,<br>neurosurgery, plastic surgery,<br>ENT and endovenous occlusion<br>of the greater saphenous vein in<br>the patient with superficial vein<br>reflux and laser assisted lipolysis<br>with a cleared compatible laser<br>marketed for the mentioned<br>intended uses and using an SMA<br>905 connector. |
| Fiber core<br>material | Silica quartz glass | Silica quartz glass |
| Fiber cladding<br>material | silica quartz glass cladding and/or<br>Hardclad<br>(depending on type of fiber) | silica quartz glass cladding<br>and/or Hardclad<br>(depending on type of fiber) |
| Buffer | silicone buffer (depending on type of<br>fiber) | silicone buffer (depending on<br>type of fiber) |
| Jacket material | silicone / ETFE /polymide /nylon /<br>acrylate / PVDF/ PU may be used<br>in the jacket depending on type of<br>fiber.<br>Color additives (see Biocompatibility<br>tests) may be included according to<br>fibers models and variants. | silicone / ETFE /polymide<br>/nylon / acrylate / PVDF/ PU<br>may be used in the jacket<br>depending on type of fiber.<br>Color additives (see<br>Biocompatibility tests) may be<br>included according to fibers<br>models and variants. |
| Maximal<br>temperature | 176°F (80°C) for nylon jacket, 302°F<br>(150°C) for ETFE jacket | 176°F (80°C) for nylon jacket,<br>302°F (150°C ) for ETFE jacket |
| Minimal bend<br>radius | 51 x core diameter (short term) 121 x<br>core diameter (long term) | 51 x core diameter (short term)<br>121 x core diameter (long term) |
| Maximal laser<br>power | Suitable for laser power up to 100W | Suitable for laser power up to<br>100W |
| Shelf life | 5 years | 5 years |
| Numerical<br>aperture range | 0.37 (for quartz/ hardclad fibers),<br>0.22 (for quartz /quartz) | 0.37 (for quartz/ hardclad fibers),<br>0.22 (for quartz /quartz) |
| Core diameter<br>range | 200 µm to 1000 µm | 200 µm to 1000 µm |
| Outer diameter<br>range | 240 µm to 1800 µm typically | 240 µm to 1800 µm typically |
| Distal fiber tip<br>types | Flat, conical, ball, spherical or<br>bended bare fibers, round or conical<br>caps | Flat, conical, ball, spherical or<br>bended bare fibers, round or<br>conical caps |
| Fiber tip outer<br>diameter range | 1.0mm to 1.8mm | 1.0mm to 1.8mm |
| Specification | Subject Device<br>neoLaser Laser Surgery<br>Fibers | Predicate Device<br>BeaMed Laser Surgery<br>Fibers |
| Wavelength range | 450nm to 2100 nm | 450nm to 2100 nm |
| Length range | 6.5 feet (2 meters) to 9.9 feet (3 meters) | 6.5 feet (2 meters) to 9.9 feet (3 meters) |
| Emission angle range | Straight, forward directed cone or 60° cone angle from fiber axis, diffuse emission, and radial 360° | Straight, forward directed cone or 60° cone angle from fiber axis, diffuse emission, and radial emission of 360° |
| Single/multiple use | Single use | Single use |
| Sterility | Sterile by EO | Sterile by EO |
| Packaging | Sterile, double pouched | Sterile, double pouched |
| Proximal end | SMA 905 connector | SMA 905 connector |

# Comparison between subiect and predicate devices

{6}------------------------------------------------

Image /page/6/Picture/0 description: The image is a logo for a company called "neolaser". The logo is set against a black background. The word "neolaser" is written in a sans-serif font, with the "neo" part in green and the "laser" part in white. A thin green line is placed underneath the word "neolaser".

7 HaEshel St., Caesarea 3088900, ISRAEL | Tel: [phone] | Fax: [phone]
[e-mail] | www.neo-laser.com | www.neo-laser.com

{7}------------------------------------------------

Image /page/7/Picture/0 description: The image is a logo for a company called "neo laser". The logo is set against a black background. The words "neo" and "laser" are written in a sans-serif font, with "neo" stacked on top of "laser". A thin green line is placed horizontally below the company name.

7 HaEshel St., Caesarea 3088900, ISRAEL | Tel: [phone] | Fax: [phone] [e-mail] | www.neo-laser.com

### Summary of performance bench testing included in the submission:

Packaging seal strength Dye penetration test Packaging microbial barrier Shelf-life validation summary Sterilization process validation plan Sterilization process validation protocol Sterilization process validation report Sterility Assurance Level (SAL) EO-ECH residuals report LAL Endotoxin test Bioburden bare fibers test / Bioburden capped fibers tests Biocompatibility tests protocols & reports Thermal safety validation

### Substantial Equivalence summary and conclusion

The neoLaser Laser Surgery Fibers and the predicate device, the BeaMed Laser Surgery Fibers (K232769) share the same indications for use, the same technical and performance characteristics, accordingly, the safety and effectiveness of the neoLaser Laser Surgery Fibers is based upon a determination of the substantial equivalence to the predicate device.

### Conclusion and substantial equivalence statement

After our analysis we have concluded that the subject device neoLaser Laser Surgery Fibers, and the predicate device the BeaMed Laser Surgery Fibers, share the same technical characteristics and the same intended use.

Accordingly, we believe that the neoLaser Laser Surgery Fibers and the legally marketed predicate, the BeaMed Laser Surgery Fibers (K232769), are substantially equivalent. Animal or clinical studies: None